Definium Therapeutics, Inc.
DFTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.9B
Close$
$2.89
93.5% downside
Current Fair Value
93.5% downsideOvervalued by 93.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.90 Billion |
|---|---|
| Enterprise Value | $4.64 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.06 |
| Beta | 2.38 |
| Outstanding Shares | 108,790,941 |
Return
| Return on Equity | -85.19% |
|---|---|
| Return on Assets | -59.19% |
| Return on Invested Capital | -59.85% |
Valuation & Multiples
| P/E Ratio | -17.98 |
|---|---|
| PEG | -7.81 |
| Price to Sales | - |
| Price to Book Ratio | 22.1 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -24.22 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2253▲ 22.53% |
|---|---|
| Total Calls | 1,531,400▲ Infinity% |
| Total Puts | 345,100▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 87.36%▲ 74.76% |
|---|---|
| Total Invested | $1.47B▲ 878.53% |
| Investors Holding | 260▲ 252.00% |
ESG Score
No data
About Definium Therapeutics, Inc.
74 employees
CEO: Robert Barrow Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized...